Zoetis delivered solid third-quarter results with a 4% revenue increase and a 9% rise in adjusted net income, showcasing resilience through a diverse product portfolio despite facing macroeconomic headwinds.

• Organic operational revenue growth of 6% in the International segment, with U.S. growth at 3% excluding the MFA divestiture.
• Companion Animal revenue rose 2%, while Livestock revenue surged 10% driven by strong market demand.
• The Simparica franchise saw 7% growth, supported by international momentum and recent approvals enhancing market reach.
• A decline of 11% in osteoarthritis franchise sales indicates challenges, with focused strategies in place for recovery.
• Upcoming product launches, including Lenivia and Portela, expected to reinforce Zoetis' leadership in chronic pain management.